Group 1 - The Hong Kong stock market experienced a strong rebound on February 23, with major indices rising significantly, including the Hang Seng Index up by 2.53% to 27,081.91 points and the Hang Seng Tech Index up by 3.34% to 5,385.35 points [1] - Various sectors showed broad-based gains, with notable performances in metals, automotive, hardware, electrical equipment, consumer discretionary retail, and chemicals, which were key drivers of the market's upward movement [1] - Major internet stocks also performed well, with Tencent Holdings increasing by 3.07% and Alibaba rising by 3.47% [1] Group 2 - Analysts from Suzhou Securities indicated that the primary driver behind the Hong Kong market's rebound was improved expectations regarding external policies, particularly adjustments in U.S. tariff policies, which could enhance profit expectations for Chinese export-oriented, technology, and consumer companies [1] - The rebound in the Hong Kong market was also in line with the overall trends in global capital markets [1] - Several local Suzhou stocks performed exceptionally well during this rebound, including Zhixing Technology, which surged by 13.3%, and semiconductor company InnoCare, which rose by 10.07%, along with over ten local biopharmaceutical stocks showing strong performance [1] Group 3 - Overall, the Hong Kong market showed an upward trend during the three trading days while the A-share market was closed, with the Hang Seng Index accumulating a rise of 1.94% and the Hang Seng Tech Index increasing by 0.47% [2] - Following the positive start in the Hong Kong market, it is expected that the A-share market will likely open higher after the holiday [2] - Sectors such as AI applications, robotics, and media are anticipated to remain active in the upcoming trading sessions [2]

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical and biotechnology industry [1] Core Insights - The pharmaceutical sector has shown a decline of 0.81% in the past week, ranking 21st among 31 primary sub-industries, while the Shanghai and Shenzhen 300 index increased by 0.36% [11][34] - Recent developments include a partnership between Heptares Therapeutics and Solstice Oncology, granting exclusive rights for HBM4003 outside Greater China, with a total upfront payment exceeding $105 million [5][12] - The report highlights the promising clinical data for HBM4003 in treating metastatic colorectal cancer, showing an objective response rate (ORR) of 34.8% and a disease control rate (DCR) of 60.9% [5][12] - Nektar Therapeutics announced positive results from the REZOLVE-AD study for moderate to severe atopic dermatitis, demonstrating sustained efficacy with the new Treg-targeting agent Rezpeg [16][19] Summary by Sections Recent Performance - The pharmaceutical sector's performance over the past month shows a decline of 0.81%, with specific sub-sectors like traditional Chinese medicine and medical devices experiencing significant drops [34] Market Dynamics - Year-to-date, the pharmaceutical sector has outperformed the Shanghai and Shenzhen 300 index by 1.79 percentage points, with a total return of 2.44% [34] Valuation - As of February 13, 2026, the pharmaceutical sector's valuation stands at 33.2 times PE, representing a 30% premium over the overall A-share market (excluding financials) [37] Key Companies to Watch - The report emphasizes companies such as Aidi Pharmaceutical, WuXi Biologics, and Innovent Biologics as key players to monitor in the current market environment [5][39]

近日，和铂医药发布公告称，公司已与SolsticeOncology签订独家授权协议及股权合作协议，授权 SolsticeOncology在大中华区以外开发及商业化HBM4003。 （和铂医药公告） (编辑：杨燕 林辰) 根据协议，公司有资格获得超过1.05亿美元的前期对价，包括5000万美元的首付款和500万美元的近期 付款，以及超过5000万美元的股权。此外，若干未来事件达成后，公司还有机会获得最高约11亿美元的 额外开发、监管及商业里程碑付款，以及基于HBM4003在大中华区以外净销售额的分级特许权使用 费。 ...

声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任 何投资建议。 | 肿瘤/肿瘤免疫 | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 项目 (合作方) | 靶点 | 适应症 | 地区 | 早期发现 | 临床前 | IND | 一期 | 二期 | 三期 | BLA | | 新一代免疫肿瘤治疗单抗 | | | | | | | | | | | | Porustobart (HBM4003) | CTLA-4 | ◆ 黑色素瘤 | 全球 | | | | | | | | | | | ◆ 结直肠癌 | 全球 | | | | | | | | | | | ◆ 肝细胞癌 | 全球 | | | | | | | | | | | ◆ 神经内分泌癌 | 全球 | | | | | | | | | *. | | | | | | | | | | | 药融圈监测显示：和铂医药与海外初创新药公司Solstice Oncology ...

【国泰海通医药】春节期间创新药领域重点新闻梳理-上市公司 恒瑞医药： 1）2/12 CDE官网显示公司递交了ANGPTL3单抗SHR-1918针对HOFH的上市申请。 目前公司暂未披露1918的III期临床结果； 1）2/20 公司公告阿美替尼已获欧洲药品管理局EMA批准在欧盟上市，用于EGFR19del或L858RNSCLC一线治疗， 以及T790MNSCLC治疗； 石药集团： 1）2/16 公司公告旗下受体偏向性GLP1/GIP激动剂月制剂SYH2082在美国获批临床； 信立泰： 翰森制药： 1）2/20 公司公告阿美替尼已获欧洲药品管理局EMA批准在欧盟上市，用于EGFR19del或L858RNSCLC一线治疗， 以及T790MNSCLC治 【国泰海通医药】春节期间创新药领域重点新闻梳理-上市公司 恒瑞医药： 1）2/12 CDE官网显示公司递交了ANGPTL3单抗SHR-1918针对HOFH的上市申请。 目前公司暂未披露1918的III期临床结果； 翰森制药： 1）2/20 公司在《欧洲呼吸杂志子刊-开放研究》ERJ OPEN RESEARCH上披露了IL17RB单抗SM17针对CRSWNP和 IPF ...

此外，和铂医药还将获得最高11亿美元的里程碑付款，以及分级销售分成。公开资料显示，Solstice Oncology为一家多个头部风险投资机构联合创立的临床阶段生物技术公司，此次合作为NewCo模式。 和铂医药-B(02142)早盘涨超8%，截至发稿，涨7.92%，报13.21港元，成交额2179.47万港元。 消息面上，2月23日，和铂医药宣布将新一代CTLA-4抗体HBM4003大中华区外全球权益授权Solstice Oncology，后者支付逾1.05亿美元前期对价，包括5000万美元首付款，500万美元近期付款以及价值逾 5000万美元的公司股权。 ...

Group 1 - Heptares Therapeutics has entered into a licensing and equity cooperation agreement with Solstice Oncology for HBM4003, granting exclusive rights for development and commercialization outside Greater China, with potential upfront payments exceeding $105 million [1] - Frontier Biotech has signed an exclusive licensing agreement with GlaxoSmithKline (GSK) for two small RNA (siRNA) pipeline products, one of which is in the IND stage, marking a significant breakthrough in its international strategy [2] - CStone Pharmaceuticals has received approval from the UK Medicines and Healthcare products Regulatory Agency for a new indication of Sugli monoclonal antibody for treating adult patients with advanced non-small cell lung cancer, highlighting its global operational capabilities [3] Group 2 - Novo Nordisk's stock has dropped significantly following the disappointing clinical data for CagriSema, which showed only a 23% weight loss effect, failing to meet the primary endpoint of the trial [4] - Tongce Medical's chairman and executives have announced plans to increase their shareholding in the company, aiming to stabilize market sentiment amid pressures from weak consumer demand and dental implant procurement [5]

丨2026年2月24日星期二丨 NO.1 和铂医药就新一代CTLA-4抗体达成授权协议及股权合作 2月23日，和铂医药公告称，公司与SOLSTICE ONCOLOGY就HBM4003订立授权协议及股权合作协 议。据此，公司同意向Solstice Oncology授予独家授权，以在大中华区以外地区开发及商业化其临床阶 段组合资产HBM4003。根据该等协议的条款，公司有资格获得价值超过1.05亿美元的前期对价。 2月23日，基石药业公告称，舒格利单抗的新适应证申请已获英国药品和医疗保健用品管理局批准单药 用于治疗肿瘤细胞PD-L1表达≥1%、无表皮生长因子受体敏感突变或ALK、ROS1基因组变异、在含铂 放化疗后未出现疾病进展的、不可切除的III期非小细胞肺癌成人患者。 点评：这是舒格利单抗出海进程的又一里程碑。不过，非小细胞肺癌领域PD-1/PD-L1竞争白热化，基 石药业需依托合作伙伴的本地化商业化能力抢占份额，本次获批更多体现监管认可度与全球化运营能力 的提升。 NO.4 诺和诺德股价大跌，CagriSema临床数据不及预期 2月23日，丹麦药企诺和诺德股价大跌。消息面上，公司公布了CagriSema临床 ...

各大券商分析师春节"连轴转" 每经记者｜王海慜 每经编辑｜何小桃 赵云 宋思艰 2026年马年春节假期，虽然A股休市，但资本市场却热度不减。 各大券商的分析师们开启"加班模式"，以高频路演、专题研报填补假期信息真空。从兴业证券策略团队的连续七天新春专题路演，到中信证券聚焦AI大模 型的系列电话会，再到多家机构跟踪春节消费动态，头部与中小券商均紧抓假期窗口输出市场观点。 《每日经济新闻》记者注意到，今年春节加班路演已经成为各券商研究所的常态，无论是中小券商还是头部券商都在假期中继续"营业"，"加更"观点。 港股马年开市两天呈现结构性行情，2月20日开市首日AI大模型、机器人板块逆势大涨，创新药、氢能概念股表现亮眼。2月20日和23日，恒生科技指数 走势先抑后扬，迎来马年"开门红"。 同时业内预计，美国此次关税裁定落地利好非美市场资产，叠加A股春节效应的历史正向表现，市场对马年节后"红包行情"的延续抱有较高期待。 截图来源：网络 最近，兴业证券策略首席张启尧的春节路演计划表在圈内刷屏：从大年初一至初七，他和团队同事一起每天15:00准时与投资者连线。 这场名为"新春专题系列"的直播，内容涵盖港股情绪研究框架、20 ...

Group 1: Market Overview - The Hang Seng Index rose by 2.29%, gaining 604 points to close at 27,017 points, while the Hang Seng Tech Index increased by 3.32% [1] - The Hong Kong stock market saw a morning trading volume of 106.5 billion HKD [1] Group 2: Optical Communication Sector - Optical communication stocks led the gains, with Longi Fiber Optics (06869) up by 15.77%, and orders for AI high-speed optical modules extending into Q4 [1] - Huizhou Technology (01729) rose over 5%, and Cambridge Technology (06166) increased by 7% [1] - Woer Cable (09981) gained 6.96% after being included in the Stock Connect list, driven by rapidly growing demand for high-speed copper cables [1] Group 3: Precious Metals Sector - The precious metals sector saw significant gains, with the International Gold Group (03939) rising over 6% to reach a historical high, expecting a year-on-year profit increase of up to 160% [1] - Zijin Gold International (02259) also rose by over 7% [1] Group 4: Technology Sector - Tech stocks rebounded, with Meituan-W (03690) increasing by over 6%, as institutions believe AI investments are entering a new phase [1] - Alibaba-W (09988) rose over 3.5%, with Alibaba Cloud adding support for four new programming models and offering lower subscription prices [1] - Hua Hong Semiconductor (01347) increased by over 4%, with expectations that its new 12-inch wafer fab will reach maximum capacity this year [1] - Biren Technology (06082) rose over 8%, having completed adaptations for several leading domestic AI models [1] Group 5: Lithium Industry - Lithium stocks strengthened, with Ganfeng Lithium (01772) rising over 8% after UBS significantly raised its domestic lithium price forecast [3] Group 6: Pharmaceutical Sector - HAP Pharmaceuticals-B (02142) increased by over 5%, with a new generation CTLA-4 antibody expected to generate over 1.2 billion USD in total [4] - Xunqi (03317) rose by over 9%, reaching a new high, with expectations of entering the Stock Connect next month, leading to a reassessment of its data circulation strategy [4] Group 7: Building Materials Sector - K. Wah Laminates (01888) rose nearly 5% to a new high, with expected annual profits exceeding 2.39 billion HKD, representing a year-on-year growth of over 80% [2]